Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix.
about
Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacyEmerging drugs for cervical cancer.Emerging drugs for the treatment of cervical cancer.Cancer drug delivery in the nano era: An overview and perspectives (Review)Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?
P2860
Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Phase II study of belotecan (C ...... e carcinoma of uterine cervix.
@en
type
label
Phase II study of belotecan (C ...... e carcinoma of uterine cervix.
@en
prefLabel
Phase II study of belotecan (C ...... e carcinoma of uterine cervix.
@en
P2093
P2860
P356
P1476
Phase II study of belotecan (C ...... e carcinoma of uterine cervix.
@en
P2093
Jong Ha Hwang
Sang-Soo Seo
Sang-Yoon Park
P2860
P304
P356
10.1093/JJCO/HYR017
P577
2011-02-24T00:00:00Z